Unjustified patents enable drug companies to charge extortionate prices for key antiretroviral drugs – particularly second and third-line drugs.

Many patents are unmerited

The cost of HIV treatment in our four focus countries is at least US$3,000 per patient per year. Companies can charge high prices because patents in each country prevent competition from manufacturers of generic drugs. Many patents on drugs are unmerited, according to the minimum standards set out in the Trade-Related Aspects of Intellectual Property Rights (TRIPS) – an international agreement administered by the World Trade Organization (WTO).

Current patent and license status of 13 drugs

On these pages we include the current patent and license status of the 13 antiretroviral drugs we are targeting. For each drug we include details of the countries in which it is patented, has patents pending, and where voluntary and compulsory licenses have facilitated some competition.